Royal College of Surgeons in Ireland
1-s2.0-S2049080122015667-main.pdf (1.01 MB)

Investigating thyroid dysfunction in the context of COVID-19 infection

Download (1.01 MB)
journal contribution
posted on 2022-12-16, 13:15 authored by Aashna Mehta, Wireko Andrew Awuah, Rohan Yarlagadda, Jacob Kalmanovich, Helen Huang, Mrinmoy Kundu, Esther Patience Nansubuga, Leilani Lopes, Bikona Ghosh, Mohammad Mehedi Hasan

COVID-19 is a contagious viral infection caused by severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2). One of the key features of COVID-19 infection is inflammation. There is increasing evidence pointing to an association between cytokine storm and autoimmunity. One autoimmune disease of interest in connection to COVID-19 is hyperthyroidism. COVID-19 has been shown to decrease TSH levels and induce thyrotoxicosis, destructive thyroiditis, and de novo Graves' disease. It has also been suggested that the immune response against SARS-CoV-2 antigens following vaccination can cross-react through a mechanism called molecular mimicry which can elicit autoimmune reactivity, potentially leading to potential thyroid disease post vaccine. However, if the COVID-19 vaccine is linked to reduced COVID-19 related serious disease, it could potentially play a protective role against post COVID-19 hyperthyroidism (de novo disease and exacerbations). Further studies investigating the complex interplay between COVID-19 or COVID-19 vaccine and thyroid dysfunction can help provide substantial evidence and potential therapeutic targets that can alter prognosis and improve COVID-19 related outcomes in individuals with or without preexisting thyroid disease. 



The original article is available at

Published Citation

Mehta A, et al. Investigating thyroid dysfunction in the context of COVID-19 infection. Ann Med Surg (Lond). 2022;84:104806.

Publication Date

31 October 2022

PubMed ID



  • Undergraduate Research


Elsevier B.V.


  • Published Version (Version of Record)